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Abstract
The comprehensiveness of data collected by “omics” modalities has demonstrated
the ability to drastically transform our understanding of the molecular mechanisms of
chronic, complex diseases such as musculoskeletal pathologies, how biomarkers are
identified, and how therapeutic targets are developed. Standardization of protocols
will enable comparisons between findings reported by multiple research groups and
move the application of these technologies forward. Herein, we describe a protocol
for parallel proteomic and metabolomic analysis of mouse intervertebral disc (IVD)
tissues, building from the combined expertise of our collaborative team. This protocol
covers dissection of murine IVD tissues, sample isolation, and data analysis for both
proteomics and metabolomics applications. The protocol presented below was optimized to maximize the utility of a mouse model for “omics” applications, accounting
for the challenges associated with the small starting quantity of sample due to small
tissue size as well as the extracellular matrix-rich nature of the tissue.
KEYWORDS
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I N T RO DU CT I O N

Mass spectrometry (MS)-based “omics” methodologies such as
proteomics and metabolomics are more nascent, with metabolomics

The advent of “omics” technologies has transformed how biological

being the most recent. As such, there is a lack of consensus on meth-

systems are investigated, and consequently how diseases are diag-

odologies for sample preparation and bioinformatic analysis.4 Proteo-

1

nosed and treated. These approaches are particularly well suited to

mics can quantitatively assess the relative abundance of thousands of

chronic, complex diseases such as musculoskeletal pathologies.2 In

proteins in a tissue or circulating in plasma with the sensitivity and

recent years, next-generation sequencing-based “omics” methodolo-

dynamic range to allow for high-throughput biological insights and

gies such as genomics and RNA-Seq have seen a drastic increase in

biomarker discovery.5 For instance, proteomics has been used to iden-

use due in part to standardization, including library preparation, instru-

tify biomarkers of mortality in older men,6 characterize the effects of

mentation, and data analysis. Over time, increased use of these meth-

sustained weight-loss,7 determine the composition of cartilage,8 and

odologies has resulted in a substantial reduction in cost, making them

how cartilage responds to injury and inflammation.9 Metabolomics

even more accessible for use by the scientific community-at-large.3

allows for the comprehensive analysis of all small molecule
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metabolites in a diseased tissue or in circulation to develop a func-

The use of unbiased “omics” approaches increases the likelihood of

tional readout of the pathological state of an organism.1 This technol-

uncovering novel pathways implicated in spine pathologies, and therefore

ogy has been used to develop biomarkers and therapeutic targets for

candidate targets for therapeutic interventions and novel biomarkers.

numerous disorders including diabetic nephropathy, renal failure, car-

Transcriptomics technologies have been applied extensively to

diovascular disease, and prostate cancer.2 Since MS-based proteomic

study the IVD, identifying numerous genes associated with IVD

and metabolomic techniques can be used for many sample types, it

degeneration in model organisms37,39,46,64,65 as well as humans.66-69

can be difficult to standardize instrument parameters, therefore opti-

In comparison, the use of proteomics has been limited, with a few

mization must be done on a sample-by-sample basis. Moreover,

studies of IVD degeneration in humans,70-72 although access to tis-

metabolomic techniques have been difficult to standardize due to dif-

sues at various stages of diseases is limited. Proteomics has also been

ferences in physicochemical properties of metabolites. The differ-

used in mice for global characterization of the healthy IVD,73 to exam-

ences in metabolite properties may necessitate the use of several

ine the response to mechanical loading,42 to characterize different

techniques (eg, LC-MS, GC-MS, NMR) to be fully comprehensive.

mouse strains,55 and to investigate ectopic calcification in the IVD.48

However, the comprehensive data collected by these “omics” modali-

To date, there have been no metabolomic studies of murine IVD tis-

ties has the potential to drastically transform our understanding of the

sues, and the analysis of human IVD tissues is limited to a single unbi-

molecular mechanisms of disease, how biomarkers are identified, and

ased metabolite screen using high-resolution magic angle spinning

how therapeutic targets are developed. Therefore, it is essential that

(HR-MAS) nuclear magnetic resonance (NMR),74 which is much less

standardized protocols be developed within specific fields of research

sensitive than MS based metabolomics.75 Despite the limitations to

to enable comparisons between findings reported by multiple

the starting quantity of sample associated with the small size of the

research groups and move the application of these technologies

mouse, it is possible to gain novel insights into mechanisms, bio-

forward.

markers and therapeutic targets of IVD pathologies using optimized

One such field of research is intervertebral disc (IVD) biology,

protocols for proteomic and metabolomic analyses.

which lacks standardization of disease models and model organisms.

Herein, we describe a protocol for parallel proteomic and

Numerous models of common spine pathologies such as IVD degener-

metabolomic analysis of mouse IVD tissues, building from the com-

ation have been reported, induced by aging,10 mechanical loading (ie,

bined expertise of our collaborative team (Figure 1). Our group has

compression11 or tail-loop12), surgical injury,13-15 or genetic manipula-

lead technical development in proteomics76-80 and applied these

tion.16-19 Many of these models have been validated in multiple model

methodologies to develop biomarker panels to improve classifications

organisms including cow, pig, sheep, goat, dog, rat, and mouse, for
which each has advantages and disadvantages.20 The lack of standardization in IVD biology can also be exemplified by recent efforts to
determine a standardized set of cell type-specific phenotypic markers.
Cell type-specific markers have been proposed either by focusing on
specific candidate genes or classes in human primary cells21-25 and
animal models,25-29 or by using unbiased whole transcriptome
approaches.30-39 Although these studies have identified a common
subset of markers that have helped to define IVD cell phenotypes,
their findings also highlight differences across species.34,39-41 This
heterogeneity in model systems and methodologies is not ideal for
exploring disease mechanisms at the molecular level that can then be
translated to the clinic.
For experimental strategies exploring the molecular mechanisms of disease, or seeking to identify disease biomarkers or therapeutic targets, a key
model organism is the mouse. This is due to the relatively short gestation
period and lifespan, ease of genetic manipulation, and robustness of bioinformatic databases compared to those of other organisms. Work by our
group and others have established the strength of mouse models to study
IVD biology and common spine disorders. We have explored the effect of
mechanical loading on the IVD in mice42-44 and used transgenic mice to
study IVD development,45 disc degeneration,16,46 and diffuse idiopathic
skeletal hyperostosis (DISH).47-50 Important insights have likewise been
provided by others using mouse models to study disc development,51-53
inflammation,54 IVD degeneration,10,13,55-58 calcification,59,60 and scoliosis.61-63 The multitude of available mouse models of spine pathologies
allows for global molecular comparisons to uncover novel biological insights.

F I G U R E 1 Schematic overview of protocol for simultaneous
assessment of proteomic and metabolomic changes
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of ovarian carcinomas,81 evaluate the potential of multipotent stromal

2

ANTICIPATED RESULTS

|

cells for pancreas regeneration,82 and developed optimized protocols
to characterize extracellular matrices,83-85 or increase the detection

Proteomics: Based on our experiments using 2- or 6-month-old

of low-abundant proteins in extracellular matrix-rich samples.86

C57/Bl6 mice, AF tissues isolated from 4 thoracic IVDs should yield

These studies led to the development of the current protocol

at least 1.5 mg of tissue (wet weight). This should lead to a total

for label-free quantitative proteomics of murine IVD tissue.48 Our

protein yield between 40 and 80 μg per sample, of which 25 μg is

group has also used metabolomics to develop biomarkers of

needed per run. With fractionation, this proteomics protocol con-

chronic kidney disease,87 muscle response to exercise in diabetes,88

sistently quantified >5000 unique proteins per sample (98% of

kidney function,89 and characterize the association of the micro-

identified proteins were quantified), a greater than 2-fold increase

biome to atherosclerosis.90 The metabolomics methods used previ-

in detection compared to our previous method that did not use

ously to assess kidney and muscle tissues required minimal

fractionation and used a different MS instrument73 (Table 1).

adaptation for use with murine IVD tissue.

Importantly, proteins are detected from all cell compartments

The protocol presented below was optimized to maximize the

(cytoplasm, nucleus, mitochondrion, plasma membrane, extracellu-

utility of a mouse model for “omics” applications, accounting for the

lar matrix) (Figure 2), suggesting this protocol reduces potential bias

challenges of minimal starting quantity of sample due to small tissue

of high-abundance extracellular matrix proteins in IVD tissue that

size as well as the extracellular matrix-rich nature of the tissue. This

could obscure low-abundance intracellular proteins.

protocol could be used to standardize tissue isolation, sample prepara-

Metabolomics: Due to the low concentration of metabolites in the

tion, fractionation, and run parameters to allow comparative analysis

IVD compared to plasma, the 300 μL of disc metabolite preparation (gen-

between datasets generated from different research groups using

erated from eight thoracic AFs; ~ 3 mg of tissue) will allow for 2 to 3 met-

mouse models to study IVD biology. The protocol was developed to

abolomics runs, if samples are pooled for a validation run with analytical

investigate proteomic and metabolomic changes in annulus fibrosus

standards. The disc metabolite preparation will not yield high-quality

tissue from the thoracic spine of a transgenic mouse model of diffuse

results after 6 months of being stored at −80 C (loss of signal intensity

idiopathic skeletal hyperostosis (DISH). For these analyses, the

due to low starting quantity), but plasma samples will last over 1 year

methods are expected to be robust and reproducible. While the

(retaining the same signal intensity). Based on this protocol, detection of

methodologies are sensitive, a primary limitation is obtaining enough

>300 features should be expected in both plasma and IVD samples

tissue from each sample (discs will have to be pooled) and ensuring

(Table 2). However, it is important to carefully consider sample size for

complete homogenization of small fibrous tissues. Incomplete

metabolomics studies, as abundance of metabolites is often highly vari-

homogenization will result in a lower number of features being

able even within sample groups. We suggest a minimum of 10 biological

detected and ultimately less peptides and metabolites being identi-

replicates stratified by sex to reduce sex-related differences in metabolite

fied. Importantly, for metabolomics, prior to experimentation, ensure

abundance. Metabolomics validation is also critical, whereby one should

the detector, lockspray and calibration setups have been performed

aim for level 1 validation by analytical standard of at least five

and the sample cone has been cleaned by sonication in formic acid.

metabolites-of-interest based on criteria developed in the field.91

In addition, our method will detect molecules with m/z between
50 and 1200. Features greater than 1200 m/z will not be captured.

Overall, the use of this protocol should be expected to provide
additional biological insights into molecular mechanisms of spine

For our specific experimental question, the protocol was

pathologies, biomarker development, and therapeutic targets beyond

designed to isolate protein and metabolites from the annulus

the use of genomics or transcriptomics alone. Furthermore, the acqui-

fibrosus of IVDs within a specific anatomical region from each

sition of data by multiple “omics” modalities from the same animal

mouse; sample isolation should therefore be more straightforward

allows for integration of multiomics datasets in the future when more

for experiments that allow for pooling of IVDs from multiple ana-

powerful bioinformatic tools are developed.

tomical regions or those focused only on one type of analysis. This
protocol is not limited to a particular genetic background of mouse
as IVD size is generally consistent across strains. Furthermore, this

3

MATERIALS

|

protocol is not limited to thoracic IVDs as lumbar and -caudal IVDs
would be even larger, and thus easier to isolate samples, though

3.1

Reagents

|

cervical IVDs may be challenging. Theoretically, this protocol could
be used for NP tissue, however, there are typically fewer NP cells

3.1.1

|

Proteomics

compared to AF cells in an IVD, so tissue yield by weight (or total
protein for proteomics) would need to be equivalent to AF, requir-

Ammonium acetate (Sigma-Aldrich, cat. no. 73594)

ing the use of more IVDs. However, using a whole IVD should not

Ammonium bicarbonate solution:

present any challenges compared to use of AF alone. Furthermore,

Prepare 50 mM ammonium bicarbonate solution by dissolving

these methodologies should be applicable to other small rodent

ammonium bicarbonate (Sigma-Aldrich, cat. no. 09830) in HPLC-grade

models such as the rat, as tissue composition is very similar, and tis-

water. This solution can be made ahead of time and stored up to

sues are even larger.

2 months at room temperature (RT).
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Sample

# unique proteins identified

# unique proteins quantified

% quantified

2 mo WT 1

5527

5404

97.8

2 mo WT 2

5418

5340

98.6

2 mo WT 3

5501

5408

98.3

2 mo KO 1

5390

5306

98.4

2 mo KO 2

5164

5095

98.7

2 mo KO 3

5294

5224

98.7

6 mo WT 1

4725

4669

98.8

6 mo WT 2

5314

5216

98.2

6 mo WT 3

4334

4216

97.3

6 mo KO 1

4825

4709

97.6

6 mo KO 2

5077

4970

97.9

6 mo KO 3

5188

5060

97.5

Average

5146

5051

98.2

Method

# unique proteins identified

McCann et al., 2016

1940

Veras et al., 2020

5146

Fold-increase in coverage

2.65-fold

TABLE 1
Number of unique
proteins identified and quantified by
proteomics

F I G U R E 2 Gene ontology (GO) cellular component enrichment for proteomics. Proteins quantified in all experimental groups (black bars) are
overlaid on the total proteins annotated to a given GO term (gray bars) for various cellular components. n = 3 mice/genotype and age
combination (2 mo WT, 2 mo KO, 6 mo WT, 6 mo KO)

8 M urea protein extraction buffer:

LC solvent A:

Prepare protein extraction buffer by mixing 50 mM ammonium

LC solvent A is 99% (vol/vol) MS-grade water, 1% (vol/vol) MS-grade

bicarbonate, 2% sodium dodecyl sulfate (SDS; Sigma-Aldrich, cat.

acetonitrile (EMD Millipore, cat. no. AX1056-1) and 0.1% (vol/vol) MS-

no. L6026) and 8 M urea (Sigma-Aldrich, cat. no. 05378) at pH 8.0.

grade formic acid (FA; EMD Millipore, cat. no. 1002641000). This solu-

The buffer should be freshly prepared.

tion can be stored at RT for up to 1 year.

DTT reducing solution:

LC solvent B:

Prepare 100 mM dithiothreitol (DTT) solution by dissolving

LC solvent B is 99% (vol/vol) MS-grade acetonitrile, 1% (vol/vol)

DTT (Sigma-Aldrich, cat. no. D9779) in HPLC-grade water. This

MS-grade water and 0.1% (vol/vol) MS-grade formic acid (FA). This

solution should be made fresh to prevent self-quenching of DTT

solution can be stored at RT for up to 1 year.

after solubilization.
IAA alkylating solution:

Lys-C Aliquot (FUJIFILM Wako Pure Chemical Corporation, cat.
no. 121-05063, 20 μg quantity):

Prepare 100 mM iodoacetamide (IAA) solution by dissolving IAA

Prepare Lys-C aliquot at a concentration of 0.04 μg/μL in 50 mM

(Sigma-Aldrich, cat. no. I1149) in HPLC-grade water. This solution

ammonium bicarbonate (ABC) by dissolving 20 μg of enzyme in

should be made fresh and protected from light.

500 μL ABC. This can be stored at −20 C for up to 1 year.
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TABLE 2
Number of features detected by metabolomics and
number meeting threshold values (fold-change ≥2 or ≤−2, P < .05)
Sample

# unique metabolites identified

Plasma

314

IVD

714
# unique metabolites meeting VIP and
pcorr thresholds

Comparison

Mass spectrometer: ThermoScientific Q Exactive Plus.
Software: MaxQuant 1.5.0.30 and Perseus 1.5.0.8 software packages used for data analysis.
Columns:
Trapping column: Waters ACQUITY UPLC M-Class Symmetry
C18 Trap Column (100 Å pore size, 1.7 μm particle size,
25 cm × 75 μm; SKU: 186007496).

6 mo WT vs 6 mo KO
Plasma

29

6 mo WT vs 6 mo KO
IVD

29

2 mo WT vs 2 mo KO
Plasma

24

2 mo WT vs 2 mo KO
IVD

42

2 mo KO vs 6 mo KO
Plasma

28

4.1.2. | Metabolomics

2 mo KO vs 6 mo KO
IVD

41

UPLC System: Waters ACQUITY UPLC I-Class.

2 mo WT vs 6 mo WT
Plasma

22

2 mo WT vs 6 mo WT
IVD

88

Analytical column: Waters ACQUITY UPLC Peptide BEH C18
column (130 Å pore size, 1.7 μm particle size, 25 cm × 75 μm;
SKU: 186003556), set column temperature to be maintained
at 35 C.

Mass spectrometer: Waters Xevo G2-S QTof.
Software: Waters MassLynx 4.1.1 software package used for data
acquisition and control of UPLC and MS parameters.
Umetrics EZinfo 2.0 software package (must be purchased) for
statistical analysis of metabolomics data.
Column: Waters ACQUITY UPLC HSS T3 (100 Å pore size,

Trypsin/Lys-C Aliquot (Promega, cat. no. V5071, 20 μg quantity):

1.8 μm particle size, 100 mm × 2.1 mm; SKU: 186003539) reverse-

Prepare Trypsin/Lys-C aliquot at a concentration of 0.04 μg/μL in

phase C18 column, set column temperature to be maintained

50 mM ammonium bicarbonate (ABC) by dissolving 20 μg of enzyme

at 45 C.

in 500 μL ABC. This can be stored at −20 C for up to 1 year.

5
3.1.2

|

EQ U I P M E N T SE T - U P / C O N D I T I O N S

|

Metabolomics
5.1

Proteomics

|

Atenolol-d7 (Toronto Research Chemicals, cat. no. A790077, 10 mg
quantity):

5.1.1

|

Liquid chromatography

Prepare a stock solution at a concentration of 1 mg/mL in 50:50
methanol:water (vol/vol, LC-MS grade). This can be stored at −20 C

Use the following LC gradient at a flow rate of 0.3 mL/min for whole

for up to 1 year.

proteome analysis (Data acquisition and analysis section: Proteomics,

Chlorpropamide (Sigma Aldrich, cat. no. C1290, 25 g quantity):

step 2):

Prepare a stock solution at a concentration of 1.38 mg/mL in
50:50 methanol:water (vol/vol, LC-MS grade). This can be stored at

Note: Gradients should be optimized for each specific column
type, LC, and solvent setups.

−20 C for up to 1 year.
DL-2-aminoheptanedioic acid (Bachem, cat. no. 4014992, 5 g quantity):

Time interval (min)

LC solvent A (%)

LC solvent B (%)

0

95

5

Flurazepam (Cerilliant, cat. no. F003, 1 mL at 1.0 mg/mL)

74

67.5

32.5

Formic acid (EMD Millipore, cat. no. 1002641000, 1 L bottle)

80

40

60

LC-MS grade acetonitrile (EMD Millipore, cat. no. AX1056-1)

81

5

95

Milli-Q water (or other LC-MS grade water) RT

90

5

95

Prepare a stock solution at a concentration of 8.75 mg/mL in LCMS grade water. This can be stored at −20 C for up to 1 year.

4

|

E Q U I P M EN T
5.1.2

|

MS analysis

4.1.1. | Proteomics
Settings for whole proteome analysis on a Q Exactive Plus MS instruUPLC system: Waters nanoACQUITY UPLC M-Class.

ment are described in the following table.
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Note: Instrument parameters may need to be adjusted slightly

5.2.2

|

MS parameters and data acquisition

due to variability in performance between MS instruments.
Note: Instrument parameters may need to be adjusted slightly due to
Method parameter

Value

Polarity

Positive

Mass range (m/z)

400-1500

variability in performance between MS instruments.
Measure metabolites in both positive and negative electrospray
ionization (ESI) modes with the following MS instrument conditions:

Micro scans

1

Resolution

70 000 @ 200 m/z

AGC target

3E6

Source temperature: 150 C.

Maximum injection time (ms)

250

Desolvation gas flow: 1000 L/h.

dd-MS2

Capillary voltage: 2.00 kV.
Cone voltage: 40 V.

Desolvation gas temperature: 500 C.

Micro scans

1

Resolution

17 500 @ 200 m/z

AGC targets

2E5

Maximum ion time (ms)

64

the MSE method in resolution mode. The MSE method allows for

Loop count

1

the simultaneous generation of precursor (function 1 of MSE

Isolation window (m/z)

2

method) and fragment ions (function 2 of MSE method) in a single

Cone gas flow: 50 L/h.
Set MS acquisition settings to acquire data in centroid, using

Isolation offset (m/z)

0

run. The acquisition period is 11 minutes, with 0.05 second scan

Fixed first mass

100

time and a mass range of 50 to 1200 Da. Set collision energy as

Normalized collision energy

25

0 V for function 1 and ramp the collision energy from 15 to 50 V

Data dependent acquisition

Top12

for function 2. Use leucine-enkephalin (500 ng/mL) as the

Threshold (counts)

2E3

lockspray solution to ensure mass accuracy. Infuse the lockspray

Minimum AGC target

3.1E4

solution at a flow rate of 10 μL/min. Set the lockmass to be

Peptide match

Preferred

Exclude isotopes

Enabled

Fragmentation type

HCD

Charge state rejection

Unassigned, +1, 7, >8

Lock mass (445.120025 m/z)

Best

Dynamic exclusion (s)

30

acquired at intervals of 10 seconds and averaged over three scans.

6

|

SAMPLE COLLECTION

All aspects of this study were conducted in accordance with the policies and guidelines set forth by the Canadian Council on Animal Care
and were approved by the Animal Use Subcommittee of the University of Western Ontario (protocol 2017-154).

5.2

Metabolomics

|

For the Waters ACQUITY system, set injection volume of 2 μL for

6.1 | Blood plasma collection (timing: ~ 5 minutes
per mouse)

plasma metabolomics, 5 μL for disc tissue metabolomics. Randomize
the sample injection order for both plasma and disc runs.
Gradient conditions are as follows.

1 Precool microcentrifuge to 4 C.
2 Weigh mice and prepare sodium pentobarbital at a concentration
of 270 mg/mL to be used at a 540 mg/kg dosage.
3 Prepare 25-gauge blood drawing needles with heparin (Sandoz, cat.

5.2.1

|

Gradient conditions

no. 10750) coating.
4 Administer sodium pentobarbital (Bimeda-MTC, cat. no. 8EUT002)
by intraperitoneal injection.

Time (min)

%B

Flow rate (mL/min)

0.0

1

0.45

2.0

60

0.45

6 Immediately transfer blood to 1.5 mL microcentrifuge tube and

6.0

85

0.45

centrifuge at 4000 RPM for 10 minutes at 4 C to separate plasma

8.0

99

0.45

from other phases.

10.0

1

0.45

11.0

1

0.45

5 Once the breathing of the mouse is slowed, perform cardiac puncture and
withdraw blood, aiming to collect 500 μL to 1 mL for an adult mouse.

7 Immediately transfer plasma supernatant (taking care to avoid the
interphase) to a new 1.5 mL microcentrifuge tube. Immediately
freeze at −80 C.
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6.2 | IVD microdissection (timing: ~30-45 minutes
per mouse)

proteomics). Label aluminum foil directly with permanent marker
(adhesive tape will fall off in liquid nitrogen).
2 Following cardiac puncture, rotate mouse to expose the dorsal

1 Fill dewar with liquid nitrogen and fold aluminum foil to create

side and douse fur with 70% ethanol in H2O (vol/vol). Make an

pouches for each mouse sample (one for metabolomics, one for

incision with scissors (length: 11.5 cm; cutting edge: 25 mm) just

F I G U R E 3 Intervertebral disc (IVD) microdissection. A-G, Removal of spinal column. H-K, Isolation of thoracic spine. L-O, Dissection of anterior thoracic
spine. P-U, IVD microdissection and AF isolation. V and W, Snap freezing in liquid nitrogen. X and Y, Repetition of previous steps for entire thoracic spine
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above the tail, taking care to cut only through the skin, and con-

7

PROTEOMI CS

|

tinue incision up to the skull (Figure 3A,B).
3 Gently peel back skin to expose the spinal column and then make

7.1

|

Protein extraction (timing: ~2 hours)

incisions on either side of the lumbar spine with scissors (through
musculature and surrounding tissues) and cut along each side of

Overview of proteomics is provided in Figure 4A.

the spine to the base of the skull (Figure 3C,D).
4 Holding at the base of the tail, lift spine from the body of the

1 Prepare protein extraction buffer (8 M urea, 50 mM ammonium

mouse (Figure 3E) to make a transverse cut through the spinal col-

bicarbonate, 10 mM dithiothreitol, and 2% SDS). Buffer should be

umn at the base of the skull (Figure 3F) to remove the intact spinal
column and rinse in PBS (Figure 3G,H).

prepared fresh.
2 Mince each IVD into approximately 8 pieces prior to homogenization.

5 Make transverse cuts within the sacral region (Figure 3I) below

3 Add 100 μL of extraction buffer to each sample and sonicate to

the bottom rib (Figure 3J) and above the top rib to isolate the cer-

homogenize at an intensity of 1 (Sonic Dismembrator Model

vical, thoracic, and lumbar spines (Figure 3K).

100, Fisher Scientific) using 25 pulses spaced 1 second apart.

Note: The remaining protocol focuses on the annulus fibrosus of

CAUTION: Always wear protective ear equipment while sonicating.

the thoracic region, but techniques should be applicable to NP or

Also, be careful to sonicate in bursts to avoid melting the sample

intact IVD from any anatomical region. Furthermore, the caudal

tube. Excessive heating of the samples in 8 M urea extraction

region can be used in the same manner as long as the skin and lig-

buffer will results in peptide carbamylation. Alternatively, sonica-

aments are removed. However, at least 3 mg of disc tissue is

tion can be done in a cold room or on ice to minimize heating.

needed to detect metabolites. Proteomics would require a minimum of 1.5 mg of disc tissue (yielding 40-80 μg of protein).

4 Clarify lysates by centrifugation at 16 000 RCF for 5 minutes at RT
and transfer supernatant to new 1.5 mL low-retention microce-

6 Isolate the anterior aspect of the thoracic spine (vertebrae + IVDs)

ntrifuge tubes (Fisher Scientific, cat. no. 02-681-320).

by inserting scissors into the vertebral foramen (Figure 3L) and

CRITICAL STEP: Always use low-retention tubes to ensure com-

cutting along the length of the spinal column directly adjacent to

plete recovery and minimize loss of peptide or proteins during MS

IVD bilaterally to remove all musculature, connective tissue and
spinous processes (Figure 3M,N).

sample preparation.
5 Measure protein concentration (in triplicate) using the Pierce

7 Use scalpel to scrape off as much soft tissue as possible surrounding the vertebrae and IVDs (Figure 3O).

660 nm protein assay (ThermoFisher Scientific, cat. no. 22662)
with a CLARIOstar Plus plate reader (BMG Labtech).

8 Use stereoscope to microdissect each individual IVD by using

CRITICAL STEP: Pierce 660 nm assay must be used since DTT will

transverse cuts where the vertebral body meets the IVD on the

interfere with quantification of protein concentrations when using

inferior (Figure 3P) and superior (Figure 3Q) side to isolate the

the BCA assay.

intact IVD.

PAUSE POINT: Samples may be stored at −80 C indefinitely for

9 Once an IVD is isolated, use a scalpel to scrape away the hard,
cartilaginous endplate from both surfaces (Figure 3R) and then lacerate the AF on one side (Figure 3S) and place IVD briefly into
PBS to allow the NP to leak out (Figure 3T; as previously

future use.
6 Reduce protein extracts using 10 mM DTT for 30 minutes at RT
with thorough vortexing.
7 Alkylate

protein

extracts

with

20 mM

iodoacetamide

for

reported46). Scrape along inner AF to remove any remaining NP

30 minutes at RT in the dark with thorough vortexing.

tissue.

PAUSE POINT: Samples can be stored at −80 C for up to 1 year.

10 Quickly transfer the AF to aluminum foil pouch (Figure 3U,V) and
immediately snap freeze in liquid nitrogen (Figure 3W). Repeat to
collect a total of four thoracic AFs adding each to a single pouch
for proteomics. Repeat to collect an additional eight thoracic AFs

7.2

|

Sample preparation (timing: 24-48 hours)

into a single pouch for metabolomics (Figure 3X,Y).
CRITICAL STEP: Leave AF tissue in PBS for as little time as possi-

1 Transfer 25 μg of protein per sample into new 1.5 mL low-

ble (~1-2 seconds), only to allow NP to leak out, as PBS can con-

retention microcentrifuge tubes for precipitation according to the

taminate

Wessel and Flügge protocol.92

mass

spectrometer

at

high

concentrations

and

metabolites can diffuse out from the tissue into PBS.
11 Once all tissues are snap frozen, remove from liquid nitrogen

CRITICAL STEP: It is imperative to keep all reagents cold for precipitation. Refrigerate methanol and chloroform until use.

and weigh to ensure a minimum of 1.8 mg of tissue for met-

2 Dilute samples with HPLC-grade H2O to total volume of 150 μL.

abolomics and 1 mg for proteomics (corresponding to ~40-80 μg

3 Add 150 μL cold chloroform (BioShop, cat. no. CCL4027) and

of protein).
12 Immediately transfer tissue to 1.5 mL low-retention microcentrifuge tubes and store at −80 C until sample preparation (up to
6 months).

650 μL methanol (Fisher Scientific, cat. no. A412) and vortex
vigorously.
4 Fill remaining volume in 1.5 mL low-retention microcentrifuge
tubes with H2O and vortex vigorously.
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CRITICAL STEP: Protein precipitate should be visible as an
opaque or white solid. If proteins are not visible, the ratios of solvents need to be adjusted by adding more HPLC-grade water.
5 Centrifuge at 14 000 RCF for 5 minutes at RT.
6 Preheat ThermoMixer to 37 C.
7 Remove the top aqueous layer from samples and discard.

12 Place samples in ThermoMixer at 37 C overnight (approximately
18 hours) at 700 RPM.
13 Add an additional aliquot of 6.25 μL Trypsin/Lys-C (1:100 enzyme
to protein ratio vol/vol) to each sample and continue mixing in
ThermoMixer at 37 C at 700 RPM for an additional 4 hours.
14 Acidify samples with 10% formic acid (pH 3-4) and centrifuge at

CRITICAL STEP: A white protein “disk” should be visible near the

14 000 RCF for 2 minutes. Remove supernatant and transfer to

interface between the chloroform and methanol-water layer.

new 1.5 mL low-retention microcentrifuge tubes.

8 Wash the protein pellet by filling sample tubes with methanol and
vortexing vigorously.
9 Centrifuge at 14 000 RCF for 5 minutes at RT.
10 Remove the top aqueous layer from samples and discard (white

CRITICAL STEP: Centrifugation must be done following acidification to remove insoluble material that will interfere with injection
into the mass spectrometer.
15 Quantify peptide concentrations with the Pierce BCA assay

protein “disk” should still be visible). Leave sample tubes open on

(ThermoFisher Scientific, cat. no. 23250).

benchtop for 5 minutes to evaporate all excess methanol.

PAUSE POINT: Samples can be stored at −80 C for up to 1 year.

CRITICAL STEP: The protein pellet can be weakly attached to the walls

16 Transfer approximately 20 μg of tryptic peptides to a new 1.5 mL

of the centrifuge tube. Take care in removing the final chloroform-

low-retention microcentrifuge tube for basic reversed-phase

methanol solution. If a protein pellet is not firmly formed against the walls

(RP) fractionation (bRP).

of the centrifuge tube, centrifuge again at 14 000 RCF for 5 minutes.

CRITICAL STEP: Due to the low starting quantity of sample

11 Add 100 μL 50 mM ABC to each sample containing 6.25 μL Lys-C

material, to maximize the number of quantifiable peptides, basic

(1:100 enzyme to protein ratio vol/vol) and 12.5 μL Trypsin/Lys-C

reversed-phase fractionation (bRP) must be performed. This

(1:50 enzyme to protein ratio vol/vol).

helps reduce bias of increased detection of matrix proteins in an

CRITICAL STEP: Do not touch protein pellet at this step as it will

extracellular matrix-rich tissue and allows detection of proteins

stick to the pipette tip and significant sample loss will occur.
Ensure the pellet is removed from the side of the tube by a short
vortex to ensure maximum surface area exposure to enzymes.

from all cell compartments.
17 Prepare StageTips by punching 12 discs of C18 using an 18-gauge
needle and packing a 200 μL StageTip.

F I G U R E 4 Schematic overview of workflow for proteomics and metabolomics. A, Proteomic workflow including homogenization (protein
extraction steps 1–7), protein isolation (sample preparation steps 1-10), protein digestion (sample preparation steps 11-15), fractionation (sample
preparation steps 16-28), and the mass spectrometry instrument. B, Metabolomic workflow including homogenization (metabolite extraction
steps 1 and 2), metal bead removal (metabolite extraction steps 3-7), addition of internal standards (sample preparation steps 1-10), validation run
(metabolite validation steps 1-7), and the mass spectrometry instrument
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18 Place tips into centrifuge and add 50 μL ACN to each tip and cen-

analysis (TruView LCMS Certified Clear Glass, Waters SKU:

trifuge at 10 000 RCF at RT for 2 minutes. Discard flow through.

186005668CV).

CRITICAL STEP: Flow through may vary, so be sure not to dry out

2 Inject up to 1 μg of peptides per sample using a nanoAcquity sys-

C18 completely. A dry C18 will not retain peptides properly.

tem (Waters, Milford, MA) and separate peptides on the analytical

Adjust speeds and time according to centrifuge.

column maintained at 35 C. Desalt all peptide samples using a trap-

19 Prepare elution buffers containing 25 mM ammonium acetate

ping column (ACQUITY UPLC M-Class Symmetry C18 Trap Col-

(pH 10) and increasing the % of ACN for each of 7 fractions as fol-

umn, 100 Å, 5 μm, 180 μm × 20 mm) for 5 minutes using Buffer A

lows: (a) 5%; (b) 7.5%; (c) 10%; (d) 12.5%; (e) 15%; (f) 17.5%;

(99% H2O, 1% acetonitrile), and separate peptides using an analyti-

(g) 50%. These solutions can be stored for up to 1 year at RT.

cal column (ACQUITY UPLC Peptide BEH C18 column, 130 Å,

20 Add ammonium acetate in 50% ACN to tips and centrifuge at

1.7 μm, 75 μm × 250 mm) using Buffer B (5.0% to 32.5% acetoni-

1000 RCF until all liquid flows through (approximately 2-3 minutes).

trile gradient over 74 minutes), followed by Buffer B 60% acetoni-

Discard flow through.

trile over 6 minutes, at a flow rate of 300 nL/min.

21 Add 100% ammonium acetate to tips to equilibrate and centrifuge

3 Proteomics data acquisition files (Raw files) are analyzed using

at 1000 RCF until all liquid flows through (approximately

the Andromeda search engine in MaxQuant with the Mouse

2-3 minutes). Discard flow through.

Uniprot Database. For all database searches, set missed

22 Turn on condenser SpeedVac (ThermoFisher Scientific) to cool

cleavages to 3, set cysteine carbamidomethylation as a fixed

(minimum 30 minutes prior to use). Preheat centrifuge attached

modification and oxidation of methionine residues, N-terminal

to condenser to 60 C to be ready when fractionation is complete.

acetylation (protein) and deamidation (NQ) were as variable

23 Resuspend peptide sample in 100 μL of ammonium acetate to

modifications, with a maximum number of modifications per

ensure the pH is ~10. Load samples onto the stage tips for centri-

peptide set to 5 and peptide length specified as ≥6. Precursor

fugation and to prepare for elution.

mass deviation set to 20 ppm and 4.5 ppm for the first and main

CRITICAL STEP: pH at least 1 sample at this step to ensure it is

searches, respectively. Fragment mass deviation set to 20 ppm.

~pH 10. Our samples were around pH 2 to begin, and pH 10 after-

For filtering, assign protein and peptide level false discover rate

ward. Determine pH by adding 1 μL sample to pH strip (Hydrion

to 0.01 (1%, for each) and decoy databases to revert. Finally,

DRJ pH 1-12, Micro Essential Laboratory cat. no. DJ-910).

enable the match between runs algorithm and leave all
remaining parameters as default.

24 Centrifuge at 1000 RCF for 5 minutes. Collect flow through and

4 Bioinformatics analyses can be performed using multiple software

reload on to StageTip.
25 Transfer the stage tips that contains bounds peptides into a new col-

packages and we recommend using the packages that accompanied

lection tube for elution of peptides using the abovementioned elution

MaxQuant called Perseus. Load in protein lists, generated from

buffers (containing 25 mM ammonium acetate and varying % of

MaxQuant as text files, in Perseus. Remove proteins that were

ACN). Centrifuge for 1000 RCF for 2-5 minutes until all liquid has

identified only by site, reverse sequences and contaminants using

flowed through.

the filter function. To further filter the proteomics dataset, remove

26 Transfer the stage tips to the next collection tube and add the

quantified proteins that were only found in one replicate using the

next elution buffer. Repeat this step 7 times until all the peptides

valid value filter in Perseus. Categorically annotate each replicate

have been eluted. Centrifuge at 1000 RCF for approximately

sample a unique name to identify each sample type using the cate-

5 minutes until all liquid has flowed through. Aim for ~20 μL/min

gorical row annotator. Perform a two-sample t-test to determine if

flow rate. The final flow through is fraction 8.

the mean of each group is significantly different, generating a list of
proteins, their fold changes and P-values for further downstream

27 To decrease total instrument time needed for peptide analysis,

analysis.

fractions 1, 7 and 8 were concatenated, leaving six total fractions.
CRITICAL STEP: Samples were combined to increase total MS time

5 Export list of proteins from Perseus using the export matrix func-

availability and to ensure each fraction had approximately the same

tion or by copy and pasting the matrix in a text or Excel document

amount of material. Concatenation strategies will be sample dependent.

for further downstream analysis.



PAUSE POINT: Samples can be stored at −80 C for 1 year.
28 Quantify fractions using the BCA assay (ThermoFisher Scientific)
and calculate volume needed for 1 μg for sample injection.

8
8.1

7.3 | Data acquisition and analysis (timing:
90 minutes per fraction, 9 hours per sample plus
additional time for data analysis)

METABOLOMICS

|
|

Metabolite extraction (timing: ~45 minutes)

Overview of metabolomics is provided in Figure 4B.
1 For metabolite extraction, transfer tissue to Navy RINO screw-cap

1 Resuspend fractionated peptide samples in 0.1% (vol/vol) formic
acid and place into deactivated glass vials designed for proteomics

tubes (Next Advance, cat. no. NAVYR1) and add 300 μL cold acetonitrile to each sample tube.
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2 Homogenize using the Bullet Blender Storm (Next Advance, cat.
no. BBY24M) set to Time: 5, and Power: 12, two times.
Note: We found that using the Bullet Blender was the most efficient method for multiple samples. However, this step is for simple

8 Prepare a new set of 1.5 mL microcentrifuge tubes (one for each
sample) and add 80 μL of LC-MS grade water to each.
9 Transfer 20 μL of supernatant into corresponding tubes containing water (1 in 5 (vol/vol) dilution in water).

tissue homogenization which could be done using a mortar and

10 Vortex the dilution for 10 seconds.

pestle with liquid nitrogen to freeze the tissue or a tissue

11 Pool a small volume from each water dilution tube (see note

homogenizer.

below) into a separate 1.5 mL microcentrifuge tube. This pooled

3 Remove the metal beads from RINO tubes using a strong magnet

sample will be used for quality control and will be injected at regu-

slid upwards slowly along the outside of the tube.

lar intervals throughout the metabolomics run.

4 Immediately place tubes into −20 C freezer for 20 minutes to

CRITICAL STEP: The amount taken from each diluted sample will
depend on the number of samples. As large metabolomics runs

allow precipitation of proteins.
5 Cool microcentrifuge to 4 C while samples are in freezer.

take a long time and the pooled sample will be injected frequently,

6 Centrifuge samples at 4 C for 5 minutes at 14 000 RCF.

you must ensure there is adequate volume to last the entire ana-

7 Remove supernatant and transfer samples to new 1.5 mL microce-

lytical run. We recommend pooling enough from each sample to
reach a total volume of 300 μL or more.

ntrifuge tubes.

12 Transfer the remaining contents of the water dilution tubes and
PAUSE POINT: Samples can be stored at −80 C for up to

the pooled sample into vials designed for MS (Deactivated Clear
Glass 12 × 32 mm Screw Neck Total Recovery Vials, Waters SKU:

6 months.

186000384DV) and cap the vials.
13 Ensure there are no air bubbles in the total recovery vials. If any

8.2

|

Sample preparation (timing: ~ 5 hours)

air bubbles are present, gently tap the bottom of vials on the
benchtop to remove the bubbles.

Total volume of solvent required for protein precipitation will depend

14 Place sample vials and pooled sample vial in 48-well plates and
place the plates into the UPLC sample manager for injection.

on number of samples to be analyzed. Acetonitrile (ACN) is the
organic solvent used in this protocol for protein precipitation. One
hundred and fifty microliters of acetonitrile solvent containing internal
standards will be added to 50 μL of each sample for protein precipitation. We recommend making 1.2 times the required amount of precip-

8.3 | LC-MS/MS acquisition (timing: 11 minutes
per sample plus controls)

itation solvent.
1 Set injection volume of 2 μL for plasma metabolomics, 5 μL for AF
1 To prepare the precipitation solvent, add chlorpropamide,

tissue metabolomics.

atenolol-d7, flurazepam, and DL-2-aminoheptanedioic acid to the

2 Randomize the sample injection order for both plasma and disc

appropriate volume of LC-MS grade acetonitrile to achieve con-

runs but keep it identical between ionization modes (ie, negative

centrations of 1.1 μg/mL, 500 ng/mL, 50 ng/mL, and 17.5 μg/mL,

ionization mode for plasma is the same order as positive ioniza-

respectively. This solution should be prepared fresh.
Note: Chlorpropamide, atenolol-d7, flurazepam, and DL-2aminoheptanedioic acid will serve as the internal standards in the

tion mode).
3 Inject pooled sample 5 times at the very beginning of the run, and
then after every five sample injections.

experiment. In our experience, using these internal standards
CRITICAL STEP: Assign group numbers (G1, G2, G3, etc) for

allows analysis of positive and negative ionization for reverse
phase chromatography.
2 Thaw samples on ice. Identical sample preparation was done for
both AF and plasma samples.
3 Aliquot 50 μL from each sample into 1.5 mL microcentrifuge
tubes.

each of your experimental groups, taking note of how you have
assigned them. When making your sample list for the analysis,
include the date of analysis and assigned group numbers in the
file names for each sample (ie, Aug23_2019_6MonthKO1_
Disc_G3_Pos).

4 Add 150 μL of ice-cold acetonitrile solvent containing internal
standards into each plasma aliquot tube for protein precipitation
(3:1 acetonitrile: plasma vol/vol).

8.4

|

Data analysis

5 Vortex tubes for 30 seconds, then incubate at −20 C for
20 minutes.

1 Copy the project folder from run, which contains the “Data” folder

6 Centrifuge at 14 000 RCF for 10 minutes.

(Waters .raw data files), to the computer where analysis will be

7 Remove and transfer 150 μL supernatant from samples into new

completed.

1.5 mL microcentrifuge tubes, being careful not to disturb the pel-

Note: We use a separate computer to analyze the data so other

let/residue at the bottom.

samples can be analyzed by LC-MS while data analysis is occurring.
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4 Paste over the existing “xset” parameters in the script with the
new parameters from IPO.

2 Open the script “Convert Waters MSe file to mzData file”

5 Change xset names to xsetP, xsetR, xsetG, xsetF ensuring that

(Supporting Information File 1) in RStudio. This script uses the con-

each xset command draws from the previous (ie, xsetR draws from

vert.waters.raw package (which will need to be installed) to convert

xsetP, xsetG draws form xsetR, etc).

.raw data files to .mzData files. Set the input folder to the full file

6 Run XCMS lines between markers labeled “here.”

path name of the “Data” folder and set the output folder to

7 Load the CAMERA package.

the same file path name of the “Data” folder, but with “/converted”

8 Use the next lines of the XCMS script to make an annotated

at the end. This will create a subfolder within “Data” called

diffreport (annotateDiffreport( ) function, part of the CAMERA

“converted” and put all the converted files into it.

package).

CRITICAL STEP: If using Windows and copying the file path name

9 Continue with the script to generated box plots and extracted ion

into RStudio, make sure the slashes separating the directories are

chromatograms for all detected metabolites with the diffreport( )

forward slashes (“/”) and not backslashes (“\”). R uses forward slashes

function. Before you do this, you will need to denote the column

to denote separate directories, whereas Windows uses backslashes.

numbers of the annotated diffreport that contain your sample

3 Run the script.
4 Once the script is finished, create a subfolder in “converted” called
“Neg.” Move all .mzData files from the negative ionization mode

groups. The groups will always start at column 13 (ie, G1, G2, G3,
and Pool are columns 13-16).
10 Repeat steps 3-9 for the positive ionization (Supporting Informa-

into the “Neg” subfolder. Within the “Neg” subfolder, create

tion File 4) mode files.

subfolders for each experimental group, including the pooled run

11 Create combined positive- and negative-ion diffreport using the

(ie, G1, G2, G3, Pool). Place all data files into their appropriate

combine XCMS script (Supporting Information File 5). The first

subfolders according to sample group.

part of this script loads in files that were saved in the previous

CRITICAL STEP: Ensure that each file has been put into the correct

scripts for negative and positive ionization modes (saved just
before the CAMERA package was loaded).

group folder. The script will not run as intended if this is not
the case.

12 Follow the rest of the script, and you will generate the files “camAnotNeg.csv” and “camAnotPos.csv”.

IPO script:

13 Use the last script (for combined annotated diffreport) to prepare
a final output file for EZInfo (Supporting Information File 6). This

The IPO script (Supporting Information File 2) is used to optimize

script will take your annotated diffreport for negative (cam-

parameters for XCMS data processing for peak picking.

AnotNeg.csv) and positive ionization (camAnotPos.csv), normalize
1 In your project folder create another subfolder called “IPO.” Inside

each mode to an internal standard, combine both modes, evaluate

“IPO,” create two folders: “IPO RPLC Neg” and “IPO RPLC Pos.”

the quality control (pooled samples) variability, and reorganize/

2 Copy the .mzData data files of all pooled injections from negative

tidy up the data for upload into EZInfo. The steps for all of these
processes are outlined in detail in the script itself.

ionization mode, minus the first five pooled injections, into the
“IPO RPLC Neg” folder created in the step above. Repeat for positive ionization mode pooled files into “IPO RPLC Pos.”

Note: This step can be done outside of R if desired.

3 Change the “setwd” and “save. image” parameters in the IPO script
to the appropriate target folders.
4 Run IPO script.

8.5

|

EZInfo analysis

5 Copy the parameters generated by IPO into a word document.
1 Proceed to EZInfo analysis to identify potential metabolites-ofXCMS script:

interest by uploading the EZInfo final sheet from the XCMS

XCMS is designed to provide automated processing of LC-MS

scripts to a new EZInfo sheet.

metabolomics data.

2 Click “View” and change the second row (Pos or Neg) to secondary variable by clicking on drop down arrow, then click “done” at

1 In your project folder, create another subfolder called “XCMS.”
Inside “XCMS,” create two folders: “XCMS RPLC Neg” and “XCMS
RPLC Pos.”
2 Copy the contents of (project)/Data/converted/Neg (ie, G1, G2,
G3, and Pool folders) to “XCMS RPLC Neg” and the contents of
(project)/Data/converted/Pos to “XCMS RPLC Pos.”
3 Open XCMS script in R (Supporting Information File 3), load the
XCMS package, and set working directory to the “XCMS RPLC
Neg” folder.

the bottom of the window.
3 Change scaling to “Pareto scaling” by clicking on the “View and
change the selected template” hyperlink and changing the “Scale
type for x-variables” to “Pareto”. Ensure that file location and
name are correct at the bottom of the window, then click “finish.”
4 Click refresh and scroll down to find principal component analysis
(PCA) plot.
5 On the right side of the window, select “color by” and change to
“sample group.”
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6 Ensure all “pooled” samples are in the center of the plot, if so,

5 Open sample list in the correct mode (Pos or Neg) in MassLynx and

delete pooled samples from EZInfo final sheet and repeat above

select the sample with the highest value for the metabolite-of-

EZInfo analysis steps.

interest. Click on “Display” then select “Mass” and type in the accu-

7 Generate Orthogonal Projections to Latent Structures Discrimi-

rate mass of the metabolite of interest (from the Excel spreadsheet)

nant Analysis (OPLS-DA) plot by clicking the box of the groups in

into the and second function in the pop-up window and hit Enter.

the legend that you want to compare. Check off OPLS-DA box at

6 Click “Tools” and select “Mass Fragment”, in the pop-up window,

the bottom of the window and click “done.”
8 Create S-plot from OPLS-DA data by clicking “S-plot” at the top
of the window. Change x-axis to p(loadings).
9 Open a new Excel spreadsheet to copy over important columns
for identification of potential metabolites-of-interest.
10 Within EZInfo, click on “Tools” tab, click “List” to retrieve p(corr)
values, click on the top corner to select all and copy to Excel.
11 Within the S-plot window in EZInfo select VIP (Variable Importance in Projection), then click “Tools,” then “List” to retrieve VIP

select the .MOL file saved from HMDB, then click “OK.”
7 A new tab will open, select the correct ionization mode and click
“Submit.”
8 View the possible fragments between the different candidate IDs
using this strategy. The lower the number beside a fragment, the
more likely it is your metabolite-of-interest.
9 Once you have determined some metabolites-of-interest, you will
need to order analytical standards to validate the metabolite ID
using the steps below.

values and copy to Excel.
12 Sort the p(corr) and VIP lists by primary ID so that they are in the
same order, then cut the VIP column and past next to p(corr).

8.7

|

Metabolite validation

Delete remaining two columns from VIP list to leave 5 columns:
Primary ID, PosOrNeg, p(1)P, p(corr), VIP.
13 Filter spreadsheet for p(corr) values greater than 0.4 or lesser than
−0.4.

To confirm the identity of metabolites of interest, analytical standards
must be purchased and run in tandem with experimental samples. If
the purchased standard has the same retention time, m/z, and frag-

14 Then sort by VIP value. VIP values >0.8 are worth attempting to
identify.

mentation spectrum as the unidentified target analyte in the experimental samples, it is considered a “level 1” (highest level possible)
identification according to a previously defined categorization system
of metabolite identification.91

8.6

|

Identification of metabolites

Steps of metabolite validation for one metabolite of interest are
as follows:

1 For each metabolite-of-interest use the human metabolome database (HMDB) at hmdb.ca. Specifically, within the “search” tab select

1 Create a stock solution of your analytical standard. The concentra-

“LC-MS Search.” This window will allow you to enter the m/z of

tion of stock solution and the solvent used will depend on the

each metabolite-of-interest. Select the correct ion mode from the

quantity of standard purchased and chemical properties of the

drop down menu and select “Unknown” for the Adduct Type. Use a
molecular weight tolerance of 0.01 to generate a stringent list of
potential metabolite IDs.
2 From the HMDB list, choose potential metabolite IDs by having a

compound, respectively.
2 For your metabolite of interest, determine which experimental
group yielded the highest average signal intensity from the metabolomics run.

low “Delta” score (meaning the actual m/z is close to theoretical m/

3 Pool plasma and/or AF samples from the experimental group with

z; 0 means exactly the same), a potentially relevant biological func-

highest average signal intensity. The amount taken from each sam-

tion and an adduct that is possible in your sample preparation. (ie,

ple will depend on the number of samples you have in that experi-

most likely adducts are multiples of hydrogen ions M + H, M − H

mental group. We recommend a total pooled volume of 100 μL.

or M + 2H, and so forth adducts adding H2O, or ACN makes sense,

4 Add your stock standard solution to LC-MS grade water and

sodiated ions, that is, M + Na are also common, potassium or

plasma/disc pooled samples to achieve a concentration of 100 μM

methyl group adducts are extremely unlikely given the ionization

and a total volume of 50 μL, creating a “spiked” water sample, and

energy in our MS method).

a “spiked” plasma/disc pooled sample. Prepare a separate aliquot of

3 To better predict the correct metabolite ID from multiple potential

50 μL of plasma/disc pooled samples with no standard added

options, download the .MOL file from each respective metabolite

(“non-spiked”).

page on HMDB and compare the fragmentation patterns using

CRITICAL STEP: Use a minimal amount of stock standard solution

Mass Fragment in MassLynx as follows.

to avoid drastically altering the composition of biological matrices.

4 For each metabolite-of-interest, click on it in the S-plot in
EZInfo and select “Variable Trend Plot” to generate a trace at
the bottom of the window. Note the sample that has the highest
value, which will be used to investigate the peak from the
chromatogram.

We recommend no more than 1% stock (v/v).
Note: 100 μM is a recommended starting point that typically results
in a strong signal for most metabolites.
5 Continue with sample preparation for “spiked” water, “spiked”
plasma/disc pooled sample, and “non-spiked” plasma/disc pooled
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Example validation run for metabolomics using phenyl sulfate identified as a level 1 metabolite

sample. Sample preparation from this point forward is identical to
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